Alpha interferon therapy of chronic delta hepatitis: a pilot study.
Di Bisceglie
A M
AM
Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Md.
Negro
F
F
Smedile
A
A
Bergmann
K
K
Hoofnagle
J H
JH
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000956:Antigens, Viral / Q000032:analysis; D002353:Carrier State; D002908:Chronic Disease; D005260:Female; D015658:HIV Infections / Q000150:complications; D006508:Hepatitis Antibodies / Q000097:blood; D006509:Hepatitis B / Q000150:complications; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006513:Hepatitis B e Antigens / Q000097:blood; D003699:Hepatitis D / Q000150:complications / Q000628:therapy*; D003698:Hepatitis Delta Virus / Q000235:genetics / Q000276:immunology; D035923:Hepatitis delta Antigens; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008099:Liver / Q000737:chemistry; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000032:analysis; D011994:Recombinant Proteins
D000956:Antigens, Viral; D006508:Hepatitis Antibodies; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D035923:Hepatitis delta Antigens; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; C442244:hepatitis delta virus large antigen; D000410:Alanine Transaminase